Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Naval Daver, Jorge Cortes, Kate Newberry, Elias Jabbour, Lingsha Zhou, Xuemei Wang, Sherry Pierce, Tapan Kadia, Koji Sasaki, Gautam Borthakur, Farhad Ravandi, Naveen Pemmaraju, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally twice daily in continuous 28-day cycles, plus 5 mg lenalidomide orally once daily on days 1-21. Thirty-one patients were treated, with a median followup of 28 months (range, 12 – 35+). Due to failure to meet the predetermined efficacy rules for treatment success the study was terminated early. Simultaneous administration of ruxolitinib and lenalidomide was difficult: 20 of the 23 dose interruptions occurred within the first 3 months of therapy. Lenalidomide was interrupted in all 20 cases. Fourteen patients (45%) were completely off lenalidomide within 3 months of initiation. Responses were noted in 17 patients (55%). The median time to response was 1.8 months (range, 0.4 – 31). All responses were International Working Group for Myelofibrosis Research and Treatment–defined clinical improvement in palpable spleen size. One spleen responder also met the criteria for clinical improvement in hemoglobin. The response rate was higher (73%) among patients who did not require early dose interruption than among those who required early interruption (45%). Improvements in bone marrow fibrosis and serial reductions in lactate dehydrogenase >50% were noted in 17% and 50% of evaluable responders, respectively. Alternate approaches such as sequential dosing need to be evaluated when considering novel combination strategies for myelofibrosis. This trial was registered with clinicaltrials.gov identifier: NCT01375140.

Original languageEnglish (US)
Pages (from-to)1058-1063
Number of pages6
JournalHaematologica
Volume100
Issue number8
DOIs
StatePublished - Aug 5 2015
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Therapeutics
Spleen
Blood Cell Count
L-Lactate Dehydrogenase
INCB018424
lenalidomide
Hemoglobins
Safety
Research

ASJC Scopus subject areas

  • Hematology

Cite this

Daver, N., Cortes, J., Newberry, K., Jabbour, E., Zhou, L., Wang, X., ... Verstovsek, S. (2015). Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica, 100(8), 1058-1063. https://doi.org/10.3324/haematol.2015.126821

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. / Daver, Naval; Cortes, Jorge; Newberry, Kate; Jabbour, Elias; Zhou, Lingsha; Wang, Xuemei; Pierce, Sherry; Kadia, Tapan; Sasaki, Koji; Borthakur, Gautam; Ravandi, Farhad; Pemmaraju, Naveen; Kantarjian, Hagop; Verstovsek, Srdan.

In: Haematologica, Vol. 100, No. 8, 05.08.2015, p. 1058-1063.

Research output: Contribution to journalArticle

Daver, N, Cortes, J, Newberry, K, Jabbour, E, Zhou, L, Wang, X, Pierce, S, Kadia, T, Sasaki, K, Borthakur, G, Ravandi, F, Pemmaraju, N, Kantarjian, H & Verstovsek, S 2015, 'Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis', Haematologica, vol. 100, no. 8, pp. 1058-1063. https://doi.org/10.3324/haematol.2015.126821
Daver, Naval ; Cortes, Jorge ; Newberry, Kate ; Jabbour, Elias ; Zhou, Lingsha ; Wang, Xuemei ; Pierce, Sherry ; Kadia, Tapan ; Sasaki, Koji ; Borthakur, Gautam ; Ravandi, Farhad ; Pemmaraju, Naveen ; Kantarjian, Hagop ; Verstovsek, Srdan. / Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. In: Haematologica. 2015 ; Vol. 100, No. 8. pp. 1058-1063.
@article{f09e56f882a74d9b89dbb74290f97aab,
title = "Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis",
abstract = "Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally twice daily in continuous 28-day cycles, plus 5 mg lenalidomide orally once daily on days 1-21. Thirty-one patients were treated, with a median followup of 28 months (range, 12 – 35+). Due to failure to meet the predetermined efficacy rules for treatment success the study was terminated early. Simultaneous administration of ruxolitinib and lenalidomide was difficult: 20 of the 23 dose interruptions occurred within the first 3 months of therapy. Lenalidomide was interrupted in all 20 cases. Fourteen patients (45{\%}) were completely off lenalidomide within 3 months of initiation. Responses were noted in 17 patients (55{\%}). The median time to response was 1.8 months (range, 0.4 – 31). All responses were International Working Group for Myelofibrosis Research and Treatment–defined clinical improvement in palpable spleen size. One spleen responder also met the criteria for clinical improvement in hemoglobin. The response rate was higher (73{\%}) among patients who did not require early dose interruption than among those who required early interruption (45{\%}). Improvements in bone marrow fibrosis and serial reductions in lactate dehydrogenase >50{\%} were noted in 17{\%} and 50{\%} of evaluable responders, respectively. Alternate approaches such as sequential dosing need to be evaluated when considering novel combination strategies for myelofibrosis. This trial was registered with clinicaltrials.gov identifier: NCT01375140.",
author = "Naval Daver and Jorge Cortes and Kate Newberry and Elias Jabbour and Lingsha Zhou and Xuemei Wang and Sherry Pierce and Tapan Kadia and Koji Sasaki and Gautam Borthakur and Farhad Ravandi and Naveen Pemmaraju and Hagop Kantarjian and Srdan Verstovsek",
year = "2015",
month = "8",
day = "5",
doi = "10.3324/haematol.2015.126821",
language = "English (US)",
volume = "100",
pages = "1058--1063",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

TY - JOUR

T1 - Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

AU - Daver, Naval

AU - Cortes, Jorge

AU - Newberry, Kate

AU - Jabbour, Elias

AU - Zhou, Lingsha

AU - Wang, Xuemei

AU - Pierce, Sherry

AU - Kadia, Tapan

AU - Sasaki, Koji

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - Pemmaraju, Naveen

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2015/8/5

Y1 - 2015/8/5

N2 - Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally twice daily in continuous 28-day cycles, plus 5 mg lenalidomide orally once daily on days 1-21. Thirty-one patients were treated, with a median followup of 28 months (range, 12 – 35+). Due to failure to meet the predetermined efficacy rules for treatment success the study was terminated early. Simultaneous administration of ruxolitinib and lenalidomide was difficult: 20 of the 23 dose interruptions occurred within the first 3 months of therapy. Lenalidomide was interrupted in all 20 cases. Fourteen patients (45%) were completely off lenalidomide within 3 months of initiation. Responses were noted in 17 patients (55%). The median time to response was 1.8 months (range, 0.4 – 31). All responses were International Working Group for Myelofibrosis Research and Treatment–defined clinical improvement in palpable spleen size. One spleen responder also met the criteria for clinical improvement in hemoglobin. The response rate was higher (73%) among patients who did not require early dose interruption than among those who required early interruption (45%). Improvements in bone marrow fibrosis and serial reductions in lactate dehydrogenase >50% were noted in 17% and 50% of evaluable responders, respectively. Alternate approaches such as sequential dosing need to be evaluated when considering novel combination strategies for myelofibrosis. This trial was registered with clinicaltrials.gov identifier: NCT01375140.

AB - Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally twice daily in continuous 28-day cycles, plus 5 mg lenalidomide orally once daily on days 1-21. Thirty-one patients were treated, with a median followup of 28 months (range, 12 – 35+). Due to failure to meet the predetermined efficacy rules for treatment success the study was terminated early. Simultaneous administration of ruxolitinib and lenalidomide was difficult: 20 of the 23 dose interruptions occurred within the first 3 months of therapy. Lenalidomide was interrupted in all 20 cases. Fourteen patients (45%) were completely off lenalidomide within 3 months of initiation. Responses were noted in 17 patients (55%). The median time to response was 1.8 months (range, 0.4 – 31). All responses were International Working Group for Myelofibrosis Research and Treatment–defined clinical improvement in palpable spleen size. One spleen responder also met the criteria for clinical improvement in hemoglobin. The response rate was higher (73%) among patients who did not require early dose interruption than among those who required early interruption (45%). Improvements in bone marrow fibrosis and serial reductions in lactate dehydrogenase >50% were noted in 17% and 50% of evaluable responders, respectively. Alternate approaches such as sequential dosing need to be evaluated when considering novel combination strategies for myelofibrosis. This trial was registered with clinicaltrials.gov identifier: NCT01375140.

UR - http://www.scopus.com/inward/record.url?scp=84938629666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938629666&partnerID=8YFLogxK

U2 - 10.3324/haematol.2015.126821

DO - 10.3324/haematol.2015.126821

M3 - Article

C2 - 26088933

AN - SCOPUS:84938629666

VL - 100

SP - 1058

EP - 1063

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -